ライフサイエンスコーパス: peritoneal dialysis

1 en and 378 in women on continuous ambulatory peritoneal dialysis).

2 are available from interventional studies in peritoneal dialysis.

3 individuals undergoing continuous ambulatory peritoneal dialysis.

4 t propensity of being initially treated with peritoneal dialysis.

5 dergoing maintenance hemodialysis or chronic peritoneal dialysis.

6 Infection is the Achilles heel of peritoneal dialysis.

7 atients more information about the option of peritoneal dialysis.

8 eration in choosing between hemodialysis and peritoneal dialysis.

9 al infection, but resulted in fibrosis after peritoneal dialysis.

10 ialysis and 41 were on continuous ambulatory peritoneal dialysis.

11 less removed from the patient during routine peritoneal dialysis.

12 adaveric renal transplants after a period of peritoneal dialysis.

13 uals with end-stage kidney disease receiving peritoneal dialysis.

14 biocompatible dialysis fluids, and automated peritoneal dialysis.

15 nal failure treated by continuous ambulatory peritoneal dialysis.

16 tients with chronic renal failure treated by peritoneal dialysis.

17 in patients undergoing continuous ambulatory peritoneal dialysis.

18 gle transport organ for small solutes during peritoneal dialysis.

19 ter transfer to hemodialysis or intermittent peritoneal dialysis.

20 ifficile peritonitis in a patient undergoing peritoneal dialysis.

21 blem in the treatment of kidney failure with peritoneal dialysis.

22 olic control in diabetic patients undergoing peritoneal dialysis.

23 eiving hemodialysis than for those receiving peritoneal dialysis.

24 F) and is a complicating factor in long-term peritoneal dialysis.

25 ults may not be generalizable to patients on peritoneal dialysis.

26 a substantial role in ultrafiltration during peritoneal dialysis.

27 itonitis compared with conventional fluid in peritoneal dialysis.

28 in an adolescent patient with HIV receiving peritoneal dialysis.

29 in very young children treated with chronic peritoneal dialysis.

30 nts received hemodialysis and fewer received peritoneal dialysis.

31 tion provided (average of information items: peritoneal dialysis [69% excellent] vs hemodialysis [30%

32 dextrose during the long dwell of automated peritoneal dialysis, a multicenter, randomized, double-b

33 15% of the prevalent patients are treated by peritoneal dialysis across the country.

34 undation-Dialysis Outcome Quality Initiative Peritoneal Dialysis Adequacy Clinical Practice Guideline

35 undation-Dialysis Outcome Quality Initiative Peritoneal Dialysis Adequacy Work Group recommended that

36 urinary oxalate values than those receiving peritoneal dialysis alone.

37 thesis that in patients undergoing automated peritoneal dialysis, an arterial pH of 7.43-7.45, as com

38 Twenty-five percent of patients undergoing peritoneal dialysis and 5% of hemodialysis patients swit

39 ke in patients who are receiving maintenance peritoneal dialysis and have evidence of malnutrition.

40 lysis did not reduce the differences between peritoneal dialysis and hemodialysis patients.

41 define "adequate" dialysis for the pediatric peritoneal dialysis and hemodialysis populations have no

42 We expect mortality rates for both peritoneal dialysis and hemodialysis to fall, however, a

43 ssues: (1) What are the equivalent doses for peritoneal dialysis and hemodialysis? (2) Are dialytic a

44 children receiving dialysis are treated with peritoneal dialysis and pediatric nephrologists report i

45 fter 7 years on hemodialysis, was changed to peritoneal dialysis and subsequently suffered two stroke

46 case of T. inkin peritonitis associated with peritoneal dialysis and the first to be treated with cas

47 h did not differ between patients undergoing peritoneal dialysis and those undergoing hemodialysis du

48 was grouped into dialysis (hemodialysis and peritoneal dialysis) and nondialysis patients and into w

49 c renal replacement therapy (hemodialysis or peritoneal dialysis), and missing peak plasma creatinine

50 ysis (hemodialysis and continuous ambulatory peritoneal dialysis), and transplantation.

51 lities, including conventional hemodialysis, peritoneal dialysis, and both continuous venovenous and

52 ge >65 years, white race, dialysis duration, peritoneal dialysis, and congestive heart failure, but n

53 s in Africa had facilities for hemodialysis, peritoneal dialysis, and kidney transplantation, respect

54 ) countries had facilities for hemodialysis, peritoneal dialysis, and kidney transplantation, respect

55 complication for surgery patients, those on peritoneal dialysis, and the critically ill.

56 Hemodialysis, peritoneal dialysis, and transplantation services were f

57 h the Dubois formula used to estimate BSA in peritoneal dialysis; and (2) comparison of percent devia

58 asibility and clinical outcomes of automated peritoneal dialysis (APD) in anuric patients.

59 The prevalence of patients on automated peritoneal dialysis (APD) is increasing worldwide and ma

60 In conclusion, compared with HD, peritoneal dialysis appears to be associated with higher

61 Although the mortality rate for peritoneal dialysis appears to be higher than that for h

62 In a mouse model of peritoneal dialysis, AqF026 enhanced the osmotic transpo

63 e hypothesis that mass transfer rates during peritoneal dialysis are dependent on the area of periton

64 r hemodialysis and the various modalities of peritoneal dialysis are reviewed in light of the state o

65 Automated forms of peritoneal dialysis are used by the majority of children

66 ld be expected to increase the efficiency of peritoneal dialysis, are not available.

67 Hemodialysis (compared with peritoneal dialysis) as initial therapy and starting dia

68 ildren in 18 countries who commenced chronic peritoneal dialysis at <24 months of age.

69 (mean age, 9.9 +/- 5.6 yr) receiving chronic peritoneal dialysis at 14 centers.

70 LE cadaveric transplant recipients receiving peritoneal dialysis before transplant compared with cont

71 bolic indices in diabetic patients receiving peritoneal dialysis but may be associated with an increa

72 Peritonitis is a major complication of peritoneal dialysis, but the relationship between perito

73 fore the initiation of continuous ambulatory peritoneal dialysis (CAPD) and 2 wk after starting the t

74 ritonitis complicating continuous ambulatory peritoneal dialysis (CAPD), a causative organism is neve

75 d, in subjects undergoing chronic ambulatory peritoneal dialysis (CAPD), and in control subjects.

76 ribe the first case of continuous ambulatory peritoneal dialysis (CAPD)-related peritonitis due to La

77 NSP occurred frequently after peritoneal dialysis catheter placement (prevalence 10% t

78 Continuous flow peritoneal dialysis (CFPD) was instituted after percutan

79 w levels of glucose degradation products for peritoneal dialysis compared with standard solutions are

80 was studied in 68 randomly selected chronic peritoneal dialysis (CPD) patients.

81 4.0 percentage points and the access gap to peritoneal dialysis decreased by 3.8 percentage points i

82 Patients with ESRD undergoing peritoneal dialysis develop progressive peritoneal fibro

83 ortion of all dialysis patients treated with peritoneal dialysis did not change in developing countri

84 ? and (3) Will survival improve by providing peritoneal dialysis doses above those currently recommen

85 n by peritoneal leukocytes isolated from the peritoneal dialysis effluent (PDE) of noninfected uremic

86 l specimens such as whole blood, plasma, and peritoneal dialysis effluent with clinically relevant de

87 dialysis patients (734 hemodialysis and 271 peritoneal dialysis) enrolled between October 1995 and J

88 Because so much evidence from the collective peritoneal dialysis experience suggested that a weekly K

89 ng heat-inactivated D39 (HI-D39) and sterile peritoneal dialysis fluid (PDF), we investigated whether

90 ll survival during exposure to glucose-based peritoneal dialysis fluid (PDF).

91 nd that endogenously generated OxPL in human peritoneal dialysis fluid from end-stage renal failure p

92 ens except for tissue, continuous ambulatory peritoneal dialysis fluid, and CSF from patients with sh

93 y in humans undergoing continuous ambulatory peritoneal dialysis for end-stage renal disease.

94 likely than adult nephrologists to recommend peritoneal dialysis for identical patients (odds ratio,

95 rgoing long-term dialysis (8 hemodialysis; 1 peritoneal dialysis) for ESRD of diverse etiologies.

96 SA) in 301 patients on continuous ambulatory peritoneal dialysis (four daily exchanges with 2-L excha

97 e assessed longitudinal trends in the use of peritoneal dialysis from 1997 to 2008 in 130 countries.

98 However, long-term peritoneal dialysis (>8 years) is limited to a small per

99 tal stroke is greater on hemodialysis versus peritoneal dialysis has not been systematically examined

100 Peritoneal dialysis has now become an established form o

101 omes in patients undergoing hemodialysis and peritoneal dialysis have improved, and current research

102 patients, studies in CKD patients undergoing peritoneal dialysis have yielded mixed results.

103 No patients undergoing peritoneal dialysis, hemodialysis, or nondialysis who ex

104 , we included the 1316 patients who received peritoneal dialysis in Australia and New Zealand from Ma

105 morbidity which ultimately limit the use of peritoneal dialysis in end-stage renal failure.

106 ement therapy, the bioartificial kidney, and peritoneal dialysis in the management of this complicate

107 significantly higher among those undergoing peritoneal dialysis in the second year (relative hazard,

108 The use of automated peritoneal dialysis increased by 14.5% in developing cou

109 s in large subjects on continuous ambulatory peritoneal dialysis is a low normalized drain volume.

110 Peritoneal dialysis is an important dialysis modality an

111 he use of a gene therapy strategy to enhance peritoneal dialysis is an innovative and exciting concep

112 though there is a perception that the use of peritoneal dialysis is declining worldwide, compilations

113 D patient treated with continuous ambulatory peritoneal dialysis is described.

114 Reimbursement for peritoneal dialysis is lower in most countries except Ge

115 in a patient receiving continuous ambulatory peritoneal dialysis is presented.

116 Convective solute transport during peritoneal dialysis is proportional to the transperitone

117 t pathways that govern solute removal during peritoneal dialysis is reviewed.

118 Peritoneal dialysis is the major renal replacement thera

119 Peritoneal dialysis is the renal replacement therapy of

120 While peritoneal dialysis is used in less than 17% of adults w

121 These data suggest that increased use of peritoneal dialysis may benefit incident ESRD patients.

122 Our results suggest that peritoneal dialysis may represent a simple and effective

123 Patients studied (hemodialysis, n = 121,970; peritoneal dialysis, n = 7129) began dialysis between 19

124 In peritoneal dialysis, new solutions using icodextrin may

125 Patients who undergo peritoneal dialysis often develop peritoneal fibrosis th

126 ional investigation for applications such as peritoneal dialysis or clinical situations associated wi

127 ificant intermethod difference by condition (peritoneal dialysis or control).

128 ified AMI patients who were receiving either peritoneal dialysis or hemodialysis before admission.

129 r who cannot undergo transplantation, either peritoneal dialysis or hemodialysis may be chosen.

130 A general assumption in peritoneal dialysis or intraperitoneal chemotherapy has

131 ay be useful in intraperitoneal therapies of peritoneal dialysis or intraperitoneal chemotherapy.

132 004 through December 2009 and either died on peritoneal dialysis or within 30 days of transfer to hem

133 stigation are paracentesis, ultrafiltration, peritoneal dialysis, oral sodium binders, vasodilator th

134 h 1.3% (95% CI, 0.5% to 2.4%) of patients on peritoneal dialysis (P=0.01), and that a statistically s

135 ropoietin doses plateaued at 30,000 units in peritoneal dialysis patients and 60,000 units in hemodia

136 tin plateaued at 3 mo in both groups: 25% in peritoneal dialysis patients and 80% in hemodialysis pat

137 Continuous ambulatory peritoneal dialysis patients are able to increase albumi

138 ons of mortality in matched hemodialysis and peritoneal dialysis patients are lacking.

139 ompare survival of incident hemodialysis and peritoneal dialysis patients by intention-to-treat analy

140 analyzed data from incident hemodialysis and peritoneal dialysis patients in 2009 who were at least 6

141 ith a 2.5-fold increase in the prevalence of peritoneal dialysis patients in developing countries.

142 month-by-month basis) U.S. hemodialysis and peritoneal dialysis patients in terms of the proportion

143 Over 12 years, the number of peritoneal dialysis patients increased in developing cou

144 yzing local and systemic immune responses in peritoneal dialysis patients presenting with acute bacte

145 Thus, use of glucose-sparing regimens in peritoneal dialysis patients should be accompanied by cl

146 om day 0, cumulative survival was higher for peritoneal dialysis patients than for hemodialysis patie

147 se to excess cases of aseptic peritonitis in peritoneal dialysis patients using icodextrin-containing

148 Excess cases of aseptic peritonitis in peritoneal dialysis patients were due to peptidoglycan c

149 O3) and sevelamer were compared in pediatric peritoneal dialysis patients with bone biopsy-proven 2 d

150 Nine peritoneal dialysis patients with mild to moderate malnu

151 ial, we randomly assigned 185 incident adult peritoneal dialysis patients with residual renal functio

152 Adult Medicare-insured hemodialysis and peritoneal dialysis patients without a history of stroke

153 In 2008, there were approximately 196,000 peritoneal dialysis patients worldwide, representing 11%

154 study suggests that in most stable automated peritoneal dialysis patients, a mean arterial pH of 7.44

155 roke in large numbers of hemodialysis versus peritoneal dialysis patients, are reviewed.

156 ng a time of improving outcomes for incident peritoneal dialysis patients, measured as reduced hazard

157 In peritoneal dialysis patients, rates rose from 5.7 in 199

158 Among the 620 peritoneal dialysis patients, stroke rates were slightly

159 es performed in actual continuous ambulatory peritoneal dialysis patients, the difference between del

160 red following intravenous bolus in 11 stable peritoneal dialysis patients.

161 composition can be readily applied to stable peritoneal dialysis patients.

162 body-composition methods in 30 well-dialyzed peritoneal dialysis patients.

163 t method of evaluating nutritional status in peritoneal dialysis patients.

164 ether the measurement was made on control or peritoneal dialysis patients.

165 s significantly associates with mortality in peritoneal dialysis patients.

166 itoneal membranes of 130 patients undergoing peritoneal dialysis (PD) and compared them with the feat

167 registry studies comparing mortality between peritoneal dialysis (PD) and hemodialysis (HD) patients

168 f life (HRQOL) between hemodialysis (HD) and peritoneal dialysis (PD) are not clearly known.

169 s (EPS) is a rare but severe complication of peritoneal dialysis (PD) characterized by extensive fibr

170 It is unclear whether peritoneal dialysis (PD) compared with hemodialysis (HD)

171 Us/mL in phosphate buffered saline (PBS) and peritoneal dialysis (PD) fluid.

172 Heat sterilization of peritoneal dialysis (PD) fluids leads to partial degrada

173 Many programs have adopted the use of peritoneal dialysis (PD) for fluid management; however,

174 l technical and nontechnical improvements in peritoneal dialysis (PD) have occurred during recent yea

175 te men, and white women who initiated HD and peritoneal dialysis (PD) in the Dialysis Morbidity and M

176 ite mupirocin prevents Staphylococcus aureus peritoneal dialysis (PD) infections but does not reduce

177 Peritoneal dialysis (PD) is a life-saving form of renal

178 Fungal peritonitis in a patient on peritoneal dialysis (PD) is a refractory injury accompan

179 l may influence the decision for the initial peritoneal dialysis (PD) modality is unknown.

180 uated the effect of hemodialysis (HD) versus peritoneal dialysis (PD) on the incidence of postoperati

181 Few studies in patients undergoing either peritoneal dialysis (PD) or hemodialysis (HD) have asses

182 ge renal disease (ESRD) maintained either on peritoneal dialysis (PD) or hemodialysis (HD).

183 Home dialysis, which comprises peritoneal dialysis (PD) or home hemodialysis (home HD),

184 In multivariate analyses, the selection of peritoneal dialysis (PD) over hemodialysis (HD) was sign

185 2-month period from the dialysis fluid of a peritoneal dialysis (PD) patient who experienced recurre

186 nts (pediatric n = 1469; adult n = 305,323); peritoneal dialysis (PD) patients (pediatric n=982; adul

187 from the blood of 20 haemodialysis (HD), 17 peritoneal dialysis (PD) patients and 20 matched control

188 afety of cinacalcet in hemodialysis (HD) and peritoneal dialysis (PD) patients with PTH > or =300 pg/

189 ion episodes, and causes of graft failure in peritoneal dialysis (PD) patients with those maintained

190 In peritoneal dialysis (PD) patients, oral iron therapy is

191 Mortality remains high in peritoneal dialysis (PD) patients.

192 Peritoneal dialysis (PD) remains limited by dialysis fai

193 gement in 1394 pediatric patients undergoing peritoneal dialysis (PD) who were prospectively followed

194 in patients undergoing hemodialysis (HD) or peritoneal dialysis (PD) with those in healthy controls.

195 rospectively analyzed 65 patients undergoing peritoneal dialysis (PD) without prior cardiovascular di

196 peritoneal membrane in patients treated with peritoneal dialysis (PD), but the underlying mechanisms

197 In patients undergoing peritoneal dialysis (PD), chronic exposure to nonphysiol

198 Technical innovations in peritoneal dialysis (PD), now used widely for the long-t

199 For patients on peritoneal dialysis (PD), the estimate is critical when

200 on peritoneal tissues in patients treated by peritoneal dialysis (PD), yet plasma levels of the AGE p

201 f 52 adult patients during episodes of acute peritoneal dialysis (PD)-associated peritonitis by multi

202 intermittent dosing of antibiotics to treat peritoneal dialysis (PD)-related peritonitis.

203 g that limits ultrafiltration in patients on peritoneal dialysis (PD).

204 itical component of dialysis prescription in peritoneal dialysis (PD).

205 tients with CKD and is further aggravated by peritoneal dialysis (PD).

206 arting treatment on hemodialysis (HD) versus peritoneal dialysis (PD).

207 l) patients incident to hemodialysis (HD) or peritoneal dialysis (PD).

208 neal membrane becomes damaged in patients on peritoneal dialysis (PD).

209 mains the main cause of technique failure in peritoneal dialysis (PD).

210 se of morbidity and mortality during chronic peritoneal dialysis (PD).

211 wed pretransplant hemodialysis (HD), and 34% peritoneal dialysis (PD).

212 ts on hemodialysis [HD] and nine patients on peritoneal dialysis [PD]) and 41 healthy control subject

213 ialysis patients (both hemodialysis [HD] and peritoneal dialysis [PD]), complete financial records (a

214 In children who are on chronic peritoneal dialysis, peritonitis is the primary complica

215 haemodialysis for inherent complications of peritoneal dialysis--peritonitis, peritoneal access, ina

216 Those who received combined hemodialysis and peritoneal dialysis pretransplant had lower posttranspla

217 s of initiating dialysis, patients receiving peritoneal dialysis rated their care higher than those r

218 tracranial hemorrhage should be treated with peritoneal dialysis rather than hemodialysis.

219 especially among elderly diabetic patients, peritoneal dialysis remains an acceptable therapy for th

220 /-8 and 1.5+/-0.9 years (34 hemodialysis, 16 peritoneal dialysis), respectively.

221 compared with satellite CvHD, home CvHD, and peritoneal dialysis, respectively.

222 d in pediatric patients with continuous flow peritoneal dialysis, resulting in a significant improvem

223 summary, the number of patients treated with peritoneal dialysis rose worldwide from 1997 to 2008, wi

224 Moreover, in patients with kidney failure, peritoneal dialysis significantly decreased glutamate co

225 th adjusted hazards for death or transfer to peritoneal dialysis slightly worsened or were unchanged

226 es and consequences in patients treated with peritoneal dialysis, so their prevention may require dif

227 Conventional peritoneal dialysis solutions (PDS) are vasoactive.

228 Glucose-containing peritoneal dialysis solutions may exacerbate metabolic a

229 the major vasoactive components of clinical peritoneal dialysis solutions.

230 Peritoneal dialysis starters had a 16% higher rate of de

231 Therefore, the decline in peritoneal dialysis take-on cannot be entirely explained

232 In the United States, chronic peritoneal dialysis take-on has declined among incident

233 patients in the United States, we found that peritoneal dialysis take-on significantly decreased from

234 k after dialysis initiation was 8% lower for peritoneal dialysis than for matched hemodialysis patien

235 The average sensitivity was 0.10 greater in peritoneal dialysis than hemodialysis patients.

236 Also, more patients undergoing peritoneal dialysis than hemodialysis switched type of d

237 It is becoming clear that during peritoneal dialysis, the peritoneal membrane undergoes v

238 ents throughout the world who are undergoing peritoneal dialysis, the tissue sources of this water fl

239 oneal membrane could improve the practice of peritoneal dialysis through the production of proteins t

240 ble survival benefit of a timely change from peritoneal dialysis to hemodialysis.

241 We developed a strategy based on peritoneal dialysis to reduce blood glutamate levels, th

242 ialysis dose and the more efficacious use of peritoneal dialysis to treat patients with end-stage ren

243 mong ESRD patients receiving hemodialysis or peritoneal dialysis, two or more values of intact PTH (i

244 Whether differences in peritoneal dialysis use among children are due to the pe

245 roke may actually be greater for patients on peritoneal dialysis versus hemodialysis in spite of thei

246 Cumulative survival probabilities for peritoneal dialysis versus hemodialysis were 85.8% versu

247 was used to compare the risk for death with peritoneal dialysis versus hemodialysis.

248 d-greater odds favoring death from stroke on peritoneal dialysis versus hemodialysis.

249 Treatment recommendations for peritoneal dialysis vs hemodialysis, compared based on n

250 ge was 70 years, and the mean time receiving peritoneal dialysis was 3 years.

251 Peritoneal dialysis was also carried out in a separate s

252 Peritoneal dialysis was associated with improved surviva

253 to normalize creatinine clearance (Ccr), in peritoneal dialysis was studied by: (1) mathematical com

254 Patients receiving peritoneal dialysis were much more likely than those rec

255 abetic renal failure patients on maintenance peritoneal dialysis were randomized to either a high or

256 Hemodialysis and peritoneal dialysis were the only forms of treatment ava

257 EM could reduce the range of indications for peritoneal dialysis, widen the range of indications for

258 uiring short- and long-term hemodialysis and peritoneal dialysis will allow appropriate planning for

259 thways for fluid and solute transport during peritoneal dialysis will permit improvements in the adeq